Powered by

Semma Therapeutics attracts funding

Mar 22, 2017 - peHUB

Cambridge, Massachusetts-based Semma Therapeutics, a developer of cell therapy for Type 1 diabetes, has raised an undisclosed amount of funding. The investor was JDRF T1D Fund, a venture philanthropy fund.


BOSTON, MA – March 22, 2017 – Semma Therapeutics, a biopharmaceutical company developing Stem Cell-derived Islet therapy for type 1 diabetes (T1D), today announced it has received an investment from the JDRF T1D Fund, a venture philanthropy fund exclusively devote...